BioDelivery Sciences International (BDSI) to Report Phase III Data of BEMA Fentanyl to Cancer Patients in April
Tweet Send to a Friend
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) plans to report Phase III data in April, regarding the efficacy of BEMA Fentanyl ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
